Amit Etkin, Alto Neuroscience CEO
Alto touts new PhIIa depression data with plans to keep charging forward
SAN FRANCISCO — Private biotech Alto Neuroscience revealed new data Tuesday morning for a psychiatric drug it’s so excited about that a follow-up study is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.